[Federal Register Volume 60, Number 213 (Friday, November 3, 1995)] [Notices] [Page 55847] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 95-27321] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health. ACTION: Notice. ----------------------------------------------------------------------- The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing. ADDRESSES: Licensing information and a copy of the U.S. patent application and/or the issued patent referenced below may be obtained by contacting the indicated Licensing Specialist at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/ 496-7735; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application. Monoclonal Antibodies for Binding HTLV-III (HIV-1) Proteins, and Cell Lines for Their Production Sarngadharan, M., Veronese, F., Gallo, R. (NCI) Serial No. 06/816,573 Patent Issued 27 June 89 U.S. Patent No. 4,843,011 Licensing Contact: Steven Ferguson, 301/496-7735 ext 266 Monoclonal antibodies and hybridoma cell lines for their production are disclosed for three specific proteins that characterize HIV-1, the virus that has been identified with AIDS. This invention relates to all monoclonal antibodies that demonstrate immune reactivity with specific antigens that identify the HIV-1 virus: p41, a transmembrane envelope glycoprotein; p24, a major core protein; and p17. These antibodies provide a means for directly detecting the virus in the sera, blood or blood products of AIDS patients or HIV-1 carriers. Such methods are an important advance over the indirect antibody detection methods presently used. Methods based on antibody detection give false negatives if no antibodies have yet been produced. These antibodies are believed to provide a positive indication of the presence of the virus at any stage of the disease in a patient or in a healthy carrier of virus. Sterile-Lyophilization Tube Kidd, G.L. (NEI) Filed 22 Sep 95 DHHS Reference No.: E-015-95/0 Licensing Contact: David Sadowski, 301/496-7735 ext. 288 Problem Addressed by This Invention: Many compounds, such as drugs, growth factors, etc., must be kept sterile and must be aliquotted for storage. Usually, these aliquots are best stored lyophilized. Yet, researchers have never had a way to keep aliquots sterile through the lyophilization process. Consequently, each aliquot has had to be filter-sterilized when reconstituted for use. This process has the disadvantages of consuming excessive filters, syringes, sterile, receptacles, and time and results in serious loss of precious sample due to absorption by the filters (especially with small aliquots less than 1 ml). Alternatively, researchers have had to forego lyophilization and store their solutions in the less-stable frozen form. Solution Offered by This Invention: Sterile-lyophilization tubes having a 0.22 micron filter built into the cap. This unique feature allows a sterile solution to remain sterile throughout lyophilization, even after the vacuum is released and air reenters the tube. Thus, a starting solution is simply filter-sterilized while in a relatively large volume, using a single filter and therefore suffering minimal loss and consuming little time. It is then aliquotted into sterile- lyophilization tubes and lyophilized. The tubes can then be transferred directly to the freezer, if desired. The compound is reconstituted when needed, and may then be used immediately without further filtration. Potential Applications of This Invention: All researchers worldwide who utilize sterile, labile compounds will have an interest in this product, including governmental, university, institutional, and drug company laboratories. Most notably in need are investigators involved in drug-testing, which is normally done either in cell cultures, laboratory animals, or humans, and which requires sterility of many aliquots of many drugs. Additionally, this product will have a large market relating to basic research utilizing microbial, plant, or animal cell or organ cultures, to which sterile compounds such as growth factors are commonly added. Research in drugs, growth factors, etc., is expanding ever more rapidly, and generally requires a cell culture system in which to study such compounds. Most of these compounds are quite expensive. Loss of potency during storage and loss of material during filtration are widespread problems which may be overcome with this invention. Therefore, there exists a tremendous need, and immense market for, this sterile-lyophilization vessel. Stage of Development: Development is complete and invention has been successfully tested. Prototypes are available. Dated: October 26, 1995. Barbara M. McGarey, Deputy Director, Office of Technology Transfer. [FR Doc. 95-27321 Filed 11-2-95; 8:45 am] BILLING CODE 4140-01-P